Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Chronic Pancreatitis II: Pathophysiology

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.

Hepatology (Baltimore, Md.)·2022

Same author

Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study.

Journal of viral hepatitis·2021

Same author

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.

The American journal of gastroenterology·2021

Same author

Evaluations of Muscular Strength, Ability to Balance and Health Status in Prisoners during COVID-19.

International journal of environmental research and public health·2021

Same author

Adipopenia Is the Rapid Screening Tool that Best Predicts Mortality in Patients with Decompensated Cirrhosis: Results of a Prospective Study.

Journal of gastrointestinal and liver diseases : JGLD·2021

Same author

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.

Drugs in context·2021

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Future directions in therapy for chronic hepatitis C.

Donald M Jensen¹, Antonio Ascione

¹Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA. djensen@medicine.bsd.uchicago.edu

Antiviral Therapy

|April 25, 2008

Summary

New antiviral therapies, including polymerase and protease inhibitors, show promise for hepatitis C virus (HCV) treatment. Combination therapy with pegylated interferon and ribavirin enhances efficacy, with pegylated interferon remaining central to HCV treatment.

Related Experiment Videos

Last Updated: Jul 5, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Hepatitis C virus (HCV) infection poses a significant global health challenge.
Current treatment strategies require optimization for improved patient outcomes.

Purpose of the Study:

To review the development of novel antiviral therapies for HCV.
To discuss the potential advances and challenges associated with new HCV treatments.

Main Methods:

Review of data from Phase I and II clinical trials of new antiviral molecules.
Analysis of polymerase and protease inhibitors for HCV treatment.
Evaluation of combination therapy including pegylated interferon and ribavirin.

Main Results:

New molecules, including polymerase and protease inhibitors, are under investigation.
Monotherapy with new agents may lead to resistance.
Combination therapy with pegylated interferon and ribavirin demonstrates significant antiviral activity.
Preliminary studies indicate new molecules are well-tolerated.

Conclusions:

Pegylated interferon is likely to remain a cornerstone of HCV therapy due to its critical role.
Further clinical studies are necessary to fully evaluate the efficacy of new antiviral agents.
Combination therapies offer improved antiviral activity and potential for HCV treatment advancement.